Consolidated statement of cash flows
January 1 to December 31, € in millions |
|
|
2024 |
|
2023 |
|
2023 previous |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating activities |
|
|
|
|
|
|
|
|
||||
Operating activities – continuing operations |
|
|
|
|
|
|
|
|
||||
Net income from continuing operations |
|
|
|
867 |
|
288 |
|
238 |
||||
Adjustments to reconcile net income from continuing operations to cash and cash equivalents provided by operating activities |
|
|
|
|
|
|
|
|
||||
Depreciation and amortization |
|
18, 19, 20, 21, 34 |
|
1,204 |
|
1,400 |
|
1,478 |
||||
Change in deferred taxes |
|
11 |
|
33 |
|
-2 |
|
-17 |
||||
Gain on sale of fixed assets and of investments and divestitures |
|
2 |
|
-1 |
|
-20 |
|
-19 |
||||
Gain / loss from the investments accounted for using the equity method |
|
|
|
-38 |
|
12 |
|
12 |
||||
Changes in assets and liabilities, net of amounts from businesses acquired or disposed of |
|
|
|
|
|
|
|
|
||||
Trade accounts and other receivables |
|
16 |
|
21 |
|
-387 |
|
-264 |
||||
Inventories |
|
17 |
|
-55 |
|
-176 |
|
-170 |
||||
Other current and non-current assets |
|
18, 19 |
|
229 |
|
-147 |
|
-224 |
||||
Accounts receivable from / payable to related parties |
|
|
|
-54 |
|
-6 |
|
6 |
||||
Trade accounts payable, provisions and other short-term and long-term liabilities |
|
23, 24, 25 |
|
146 |
|
1,011 |
|
986 |
||||
Liabilities for income taxes |
|
|
|
49 |
|
104 |
|
105 |
||||
Net cash provided by operating activities – continuing operations |
|
|
|
2,401 |
|
2,077 |
|
2,131 |
||||
Net cash provided by operating activities – deconsolidated Fresenius Medical Care operations under IFRS 5 |
|
|
|
n.a. |
|
2,325 |
|
2,325 |
||||
Net cash provided by operating activities – discontinued operations |
|
|
|
46 |
|
54 |
|
n.a. |
||||
Net cash provided by operating activities |
|
|
|
2,447 |
|
4,456 |
|
4,456 |
||||
Investing activities |
|
|
|
|
|
|
|
|
||||
Investing activities – continuing operations |
|
|
|
|
|
|
|
|
||||
Purchases of property, plant and equipment and capitalized development costs |
|
20 |
|
-923 |
|
-1,053 |
|
-1,134 |
||||
Proceeds from sales of property, plant and equipment |
|
|
|
7 |
|
27 |
|
27 |
||||
Acquisitions and investments and purchases of intangible assets |
|
2, 37 |
|
-80 |
|
-233 |
|
-234 |
||||
Proceeds from sale of investments and divestitures |
|
2, 37 |
|
394 |
|
1 |
|
1 |
||||
Cash and cash equivalents disposed of from the deconsolidation of Fresenius Medical Care |
|
|
|
n.a. |
|
-1,303 |
|
-1,303 |
||||
Dividends received from Fresenius Medical Care |
|
|
|
112 |
|
106 |
|
n.a. |
||||
Net cash used in investing activities – continuing operations |
|
|
|
-490 |
|
-2,455 |
|
-2,643 |
||||
Net cash used in investing activities – deconsolidated Fresenius Medical Care operations under IFRS 5 |
|
|
|
n.a. |
|
-650 |
|
-544 |
||||
Net cash used in investing activities – discontinued operations |
|
|
|
-20 |
|
-82 |
|
n.a. |
||||
Net cash used in investing activities |
|
|
|
-510 |
|
-3,187 |
|
-3,187 |
||||
Financing activities |
|
|
|
|
|
|
|
|
||||
Financing activities – continuing operations |
|
|
|
|
|
|
|
|
||||
Proceeds from short-term debt |
|
26 |
|
52 |
|
414 |
|
433 |
||||
Repayments of short-term debt |
|
26 |
|
-496 |
|
-61 |
|
-75 |
||||
Proceeds from long-term debt |
|
26 |
|
10 |
|
1,316 |
|
1,336 |
||||
Repayments of long-term debt |
|
26 |
|
-546 |
|
-1,123 |
|
-1,040 |
||||
Repayments of lease liabilities |
|
34 |
|
-181 |
|
-186 |
|
-232 |
||||
Proceeds from the issuance of bonds |
|
27 |
|
240 |
|
790 |
|
790 |
||||
Repayments of liabilities from bonds |
|
27 |
|
-700 |
|
-450 |
|
-450 |
||||
Repayments of convertible bonds |
|
28 |
|
-500 |
|
– |
|
– |
||||
Dividends received from Fresenius Medical Care |
|
|
|
– |
|
– |
|
106 |
||||
Dividends paid |
|
|
|
– |
|
-551 |
|
-550 |
||||
Change in noncontrolling interests, net |
|
30 |
|
-13 |
|
-24 |
|
-24 |
||||
Net cash used in / provided by financing activities – continuing operations |
|
|
|
-2,134 |
|
125 |
|
294 |
||||
Net cash used in financing activities – deconsolidated Fresenius Medical Care operations under IFRS 5 |
|
|
|
n.a. |
|
-1,565 |
|
-1,671 |
||||
Net cash used in / provided by financing activities – discontinued operations |
|
|
|
-49 |
|
63 |
|
n.a. |
||||
Net cash used in financing activities |
|
|
|
-2,183 |
|
-1,377 |
|
-1,377 |
||||
Effect of exchange rate changes on cash and cash equivalents |
|
|
|
-2 |
|
-43 |
|
-43 |
||||
Net decrease in cash and cash equivalents |
|
|
|
-248 |
|
-151 |
|
-151 |
||||
Cash and cash equivalents at the beginning of the reporting period |
|
15 |
|
2,562 |
|
2,749 |
|
2,749 |
||||
less cash and cash equivalents at the end of the reporting period shown under “assets held for sale” |
|
|
|
32 |
|
36 |
|
36 |
||||
Cash and cash equivalents at the end of the reporting period |
|
15 |
|
2,282 |
|
2,562 |
|
2,562 |
||||
|
||||||||||||
January 1 to December 31, € in millions |
|
|
2024 |
|
2023 |
|
2023 previous |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Received interest |
|
|
|
72 |
|
93 |
|
96 |
||||||
Paid interest |
|
|
|
-415 |
|
-389 |
|
-403 |
||||||
Income taxes paid |
|
|
|
-430 |
|
-349 |
|
-356 |
||||||
|
||||||||||||||